Try
Bausch + Lomb Corporation Common Shares
BLCOUnited States
19 filed reports · 345 financial concepts · 1 earnings calls · 0 media appearances
Filed reports
19 reports · Mar 2022 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 4 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 14 | 3,708 | Mar 2022 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 4 | 2,847 | Dec 2022 to Dec 2025 |
| Current · 8-KSEC EDGAR | 1 | 4 | Jun 2026 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Jul 29, 2026 | 473 | Open |
| FY2026 Q2 | 8-K | Jun 30, 2026 | Jul 29, 2026 | 4 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | Apr 29, 2026 | 341 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 18, 2026 | 1,288 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Oct 29, 2025 | 355 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Jul 30, 2025 | 213 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | Apr 30, 2025 | 218 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 19, 2025 | 578 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Oct 30, 2024 | 306 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 1, 2024 | 225 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 1, 2024 | 231 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Feb 21, 2024 | 553 | Open |
Financial data
345 concepts · 6,559 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial328 concepts · 4,883 facts · Dec 2020 to Jul 2026
- Allowance for doubtful accounts receivable31 · Dec 2020 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents31 · Dec 2020 to Jun 2026
- Stockholders equity including portion attributable to noncontrolling interest31 · Dec 2020 to Jun 2026
- Valuation allowances and reserves balance31 · Dec 2020 to Jun 2026
- Allocated share based compensation expense28 · Dec 2020 to Jun 2026
- Allowances for losses on trade receivables and inventories28 · Dec 2020 to Jun 2026
- Amortization of intangible assets28 · Dec 2020 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect28 · Dec 2020 to Jun 2026
- Comprehensive income net of tax28 · Dec 2020 to Jun 2026
- Comprehensive income net of tax attributable to noncontrolling interest28 · Dec 2020 to Jun 2026
- Comprehensive income net of tax including portion attributable to noncontrolling interest28 · Dec 2020 to Jun 2026
- Costs and expenses28 · Dec 2020 to Jun 2026
- Deferred income taxes28 · Dec 2020 to Jun 2026
- Depreciation and amortization28 · Dec 2020 to Jun 2026
- Effect of exchange rate on cash cash equivalents restricted cash and restricted cash equivalents28 · Dec 2020 to Jun 2026
- Foreign currency transaction gain loss before tax28 · Dec 2020 to Jun 2026
- Foreign currency transaction gain loss unrealized28 · Dec 2020 to Jun 2026
- Goodwill (US GAAP)28 · Dec 2020 to Jun 2026
- Income tax expense benefit28 · Dec 2020 to Jun 2026
- Increase decrease in accounts payable and accrued liabilities28 · Dec 2020 to Jun 2026
- Increase decrease in accounts receivable28 · Dec 2020 to Jun 2026
- Increase decrease in inventories28 · Dec 2020 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets28 · Dec 2020 to Jun 2026
- Interest expense debt28 · Dec 2020 to Jun 2026
Segment11 concepts · 1,093 facts · Dec 2020 to Jun 2026
- Revenue623 · Dec 2020 to Jun 2026
- Operating income loss90 · Dec 2020 to Jun 2026
- Cost of goods and services sold (US GAAP)84 · Dec 2022 to Jun 2026
- Goodwill foreign currency translation gain loss81 · Dec 2020 to Jun 2026
- Goodwill76 · Dec 2020 to Jun 2026
- Research and development expense excluding acquired in process cost42 · Dec 2022 to Jun 2026
- Selling general and administrative expense42 · Dec 2022 to Jun 2026
- Goodwill acquired during period32 · Dec 2022 to Dec 2025
- Payments to acquire productive assets14 · Dec 2020 to Dec 2023
- Goodwill other increase decrease5 · Dec 2021
- Bausch + Lomb4 · Dec 2020
Geography2 concepts · 327 facts · Dec 2020 to Dec 2025
- Revenue322 · Dec 2020 to Dec 2025
- Accounts Receivable, Net5 · Dec 2022 to Dec 2025
Product2 concepts · 252 facts · Dec 2020 to Jun 2026
- Revenue196 · Dec 2020 to Jun 2026
- Cost of goods and services sold (US GAAP)56 · Dec 2020 to Jun 2026
Guidance2 concepts · 4 facts · Jul 2026
- Revenue Growth Guidance2 · Jul 2026
- Revenue Guidance2 · Jul 2026
Segments
1,672 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments9 members · 1,093 facts
- Surgical320 · Dec 2020 to Jun 2026
- Vision Care319 · Dec 2020 to Jun 2026
- Pharmaceuticals267 · Dec 2021 to Jun 2026
- Ophthalmic Pharmaceuticals99 · Dec 2020 to Mar 2023
- Surgical25 · Dec 2020 to Jun 2026
- Vision care25 · Dec 2020 to Jun 2026
- Pharmaceuticals17 · Dec 2022 to Jun 2026
- Bausch Lomb12 · Dec 2020 to Dec 2023
- Ophthalmic pharmaceuticals9 · Dec 2020 to Mar 2023
Statement geographical20 members · 327 facts
- CA22 · Dec 2020 to Dec 2025
- CN22 · Dec 2020 to Dec 2025
- DE22 · Dec 2020 to Dec 2025
- ES22 · Dec 2020 to Dec 2025
- FR22 · Dec 2020 to Dec 2025
- GB22 · Dec 2020 to Dec 2025
- IT22 · Dec 2020 to Dec 2025
- JP22 · Dec 2020 to Dec 2025
- KR22 · Dec 2020 to Dec 2025
- MX22 · Dec 2020 to Dec 2025
- Other Countries22 · Dec 2020 to Dec 2025
- PL22 · Dec 2020 to Dec 2025
- RU22 · Dec 2020 to Dec 2025
- United Statesand Puerto Rico22 · Dec 2020 to Dec 2025
- AU6 · Mar 2022 to Sep 2023
- Algeria argentina brazil belarus greece iran russia serbia south africa turkey ukraine and venezuela4 · Dec 2022 to Dec 2025
- BY3 · Dec 2020 to Dec 2022
- UA3 · Dec 2020 to Dec 2022
- SE2 · Mar 2021 to Mar 2022
- Argentina brazil belarus greece russia serbia south africa turkey ukraine and venezuela1 · Dec 2022
Product or service7 members · 252 facts
- Product56 · Dec 2020 to Jun 2026
- Product And Service Other56 · Dec 2020 to Jun 2026
- Brandedand Other Generic Products28 · Dec 2020 to Jun 2026
- Device Products28 · Dec 2020 to Jun 2026
- Other Revenues28 · Dec 2020 to Jun 2026
- Overthe Counter Products28 · Dec 2020 to Jun 2026
- Pharmaceutical Products28 · Dec 2020 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary99 claims from 8 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary171 claims from 7 reports · Sep 2024 to Jun 2026
- Risk-factor changes16 claims from 1 reports · Dec 2025
- Risk factors108 risks from 2 annual reports · 2024 to 2025
Earnings calls
1 calls · Jul 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Jul 29, 2026
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 17, 2026) and refreshed every few hours.